• No results found

CAR-T cells

Engineering CAR-T cells

Engineering CAR-T cells

... for T cell activation. Three different receptor types including the T-cell antigen receptors, cytokine receptors and co- stimulatory receptors are included in this ...of T cells and avoid ...

6

Prospects for combined use of oncolytic viruses and CAR T-cells

Prospects for combined use of oncolytic viruses and CAR T-cells

... and CAR T-cell ...indeed CAR T-cells) be achieved by local intra-tumoural injection or by systemic parenteral delivery? Which CAR intracellular domain/construct may be most ...

27

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

... ond CART cell infusions. Five patients treated in our study with CART cells after Cy-based lymphodepletion had persistent leu- kemia or subsequently relapsed and received a second ...

17

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

New Strategies for the Treatment of Solid Tumors with CAR-T Cells

... of T cells ...Therefore, CAR-T cells that targeting WT1 is a good improvement ...modified CAR-T cells, containing the antigen recognition domain derived from fully ...

12

Incorporation of functional elements enhances the antitumor capacity of CAR T cells

Incorporation of functional elements enhances the antitumor capacity of CAR T cells

... anti-CAIX CAR T cells alone in a humanized mice model of clear cell renal cell carcinoma ...NK cells to the tumor ...HER2.CAR T cells alone or with HER2.CAR ...

5

Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity

... advancing CAR T cell therapy is the ability to manufacture CAR T cells that are capable of maintaining a long-term antitumor ...the CAR T cell product focuses on the ...

19

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity

Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity

... of CAR T cells cultured in different sera, we engrafted mice ...PSCA cells, followed by i.v. administration of GFP/FL-labeled P28z T cells once tumors had reached ~ 100 mm 3 ...

15

The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma

The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma

... EGFR-CAR T-cells in comparison to CART control in the presence of target cells and nontarget cells, we verified the antitumor effects of EGFR-CAR ...target cells, ...

7

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization

... CD19-DARIC T cells were able to control tumor growth at nonimmunosuppressive rapamycin ...Nalm-6–FFluc cells were inoculated into NSG mice and CD19-DARIC or CD19-CAR T cells were ...

19

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

... T cells that are redirected to single tumor ...bispecific CAR molecule would mitigate antigen escape and improve the antitumor activity of T ...a CAR that joins a HER2-binding scFv and ...

18

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia

... CLL-1 CAR-T cells may not be appropriate for patient with M6 developed from erythrocyte, unless accompanied by abnormal myeloid hematopoietic cell ...CLL-1 CAR-T cells are ...

13

Patient-derived glioblastoma stem cells are killed by CD133- specific CAR T cells but induce the T cell aging marker CD57

Patient-derived glioblastoma stem cells are killed by CD133- specific CAR T cells but induce the T cell aging marker CD57

... AC133- CAR T cells kill AC133+ GBM stem cells (GBM-SCs) both in vitro and in an orthotopic tumor model in ...the CAR T cells, a molecule known to mark terminally or near- ...

14

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

... 19/22 cells; thus, we used a lower-dose methylprednisolone at 20 mg daily as the initial dose followed by elegant titratable dosing in an effort to partially treat GVHD or slow down the GVHD exacerba- tion but ...

9

Frβ-Directed Car T Cells for Immunotherapy of Cancer

Frβ-Directed Car T Cells for Immunotherapy of Cancer

... of CAR T cells at late stages of tumor ...term CAR T cell persistence and ...of CAR T cells led to rapid depletion of T cells following later doses ...

214

Clinical trials of CAR-T cells in China

Clinical trials of CAR-T cells in China

... (CAR)-engineered T cells are widely studied for cancer ...CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical ...testing CAR designs ...

10

Universal CARs, universal T cells, and universal CAR T cells

Universal CARs, universal T cells, and universal CAR T cells

... approved T cell products with chimeric antigen receptors (CAR) are from autologous T ...These CAR T cells approved for clinical use must be generated on a custom-made ...

9

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

... ALL cells, a penta-valent CD22 CAR was designed and expressed in the bi-specific CAR T ...the CAR T cells de- signed to simultaneously target CD19 and CD22 ...anti-CD19 ...

11

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses

... meso-CAR T therapies. Tar- get antigen loss and T cell hypofunction or insufficient tumor infiltration are major causes of tumor relapse for adoptive cell therapies ...meso-CAR T cell ...

18

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

... MOv19-27z CAR T cells appeared slightly better than that of C4-27z CAR T cells, but were statistically similar even at the final time point (p = ...after T cells ...

14

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

... antigen-targeted CAR-T cells is being tested as a strat- egy to reduce relapse ...targeted CAR-T cell therapies at present include the fol- lowing: (I) Pooled CAR-T ...

10

Show all 10000 documents...

Related subjects